Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 35, 2024 - Issue 1
Submit an article Journal homepage
1,126
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

The effect of tildrakizumab on adipokines production in patients affected by psoriasis and obesity: preliminary results from a single center real-life study

Sara CacciapuotiSection of Dermatology – Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, ItalyView further author information
,
Matteo MegnaSection of Dermatology – Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, ItalyView further author information
,
Emanuela SalzaSection of Dermatology – Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, ItalyView further author information
,
Luca PotestioSection of Dermatology – Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, ItalyORCID Iconhttps://orcid.org/0000-0001-5940-0592View further author information
ORCID Icon &
Giuseppina CaiazzoSection of Dermatology – Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, ItalyView further author information
Article: 2291323 | Received 01 Dec 2023, Accepted 01 Dec 2023, Published online: 18 Dec 2023

References

  • Griffiths CEM, Armstrong AW, Gudjonsson JE, et al. Psoriasis. Lancet. 2021;397(10281):1–3. doi: 10.1016/S0140-6736(20)32549-6.
  • Jensen P, Skov L. Psoriasis and obesity. Dermatology. 2016;232(6):633–639. doi: 10.1159/000455840.
  • Kiełbowski K, Bakinowska E, Ostrowski P, et al. The role of adipokines in the pathogenesis of psoriasis. Int J Mol Sci. 2023;24(7):6390. doi: 10.3390/ijms24076390.
  • Filková M, Haluzík M, Gay S, et al. The role of resistin as a regulator of inflammation: implications for various human pathologies. Clin Immunol. 2009;133(2):157–170. doi: 10.1016/j.clim.2009.07.013.
  • Brennan AM, Mantzoros CS. Drug insight: the role of leptin in human physiology and pathophysiology–emerging clinical applications. Nat Clin Pract Endocrinol Metab. 2006;2(6):318–327. doi: 10.1038/ncpendmet0196.
  • Ruggiero A, Camela E, Potestio L, et al. Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge. Expert Opin Drug Saf. 2022;21(12):1445–1451. doi: 10.1080/14740338.2022.2160447.
  • Ruggiero A, Fabbrocicni G, Cacciapuoti S, et al. Tildrakizumab for the treatment of moderate-to-severe psoriasis: results from 52 weeks real-life retrospective study. Clin Cosmet Investig Dermatol. 2023;16:529–536. doi: 10.2147/CCID.S402183.
  • Elgaard CDB, Iversen L, Hjuler KF. Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis. J Dermatolog Treat. 2023;34(1):2133531.
  • Ruggiero A, Potestio L, Cacciapuoti S, et al. Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real-life study. Dermatol Ther. 2022;35(12):e15941.
  • Camela E, Potestio L, Fabbrocini G, et al. The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs. Expert Opin Investig Drugs. 2023;32(6):537–552. doi: 10.1080/13543784.2023.2219387.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.